Disease Overview：DVT-induced Pulmonary Embolism（DVT-related PE）
Deep Vein Thrombosis (DVT)-induced Pulmonary Embolism (PE) is a life-threatening condition arising when a thrombus forms in the deep venous system—most commonly the iliofemoral veins—and subsequently dislodges, traveling via the right heart to occlude pulmonary arterial branches. This acute event triggers abrupt dyspnea, pleuritic chest pain, hemoptysis, tachycardia, and hypoxemia; severe cases may present with hemodynamic instability or sudden cardiac arrest. Risk factors include prolonged immobility, major surgery, malignancy, inherited thrombophilias (e.g., Factor V Leiden), pregnancy, and oral contraceptive use. Diagnosis relies on clinical assessment (Wells score), D-dimer testing, and confirmatory imaging—primarily CT pulmonary angiography (CTPA) or ventilation-perfusion (V/Q) scintigraphy. Management encompasses anticoagulation (direct oral anticoagulants or low-molecular-weight heparin), risk-stratified reperfusion therapy (systemic thrombolysis or catheter-directed thrombectomy), and long-term secondary prevention. Early intervention significantly reduces mortality, which can exceed 30% in untreated high-risk PE.
China offers distinct advantages for international patients seeking DVT-PE care. Leading tertiary hospitals—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—maintain dedicated Pulmonary Vascular Disease Centers staffed by nationally certified pulmonologists and interventional radiologists with extensive experience in complex PE management. Advanced capabilities include real-time 3D rotational angiography, ultrasound-guided catheter-directed thrombolysis, and hybrid operating suites enabling simultaneous medical and mechanical interventions. Clinical outcomes align with international benchmarks: multi-center studies report 92–95% technical success rates for catheter-based therapies and <5% 30-day mortality in intermediate-high-risk PE. Crucially, treatment costs—including diagnostics, hospitalization, and targeted interventions—are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or accreditation standards (JCI- or CNAS-certified facilities). As a specialized medical tourism agency, we facilitate seamless access to these resources: coordinating appointments with top-tier specialists, providing itemized, transparent pricing in advance, arranging visa support, medical translation, accommodation, and post-discharge follow-up—all tailored to individual clinical needs and logistical requirements.
DVT-induced Pulmonary Embolism: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Deep Vein Thrombosis–Induced Pulmonary Embolism (Respiratory Medicine)
Non-Surgical / Conservative Management
*Target Criteria:* Low-to-intermediate risk PE (PESI ≤ 60, sPESI = 0), hemodynamically stable, no contraindications to anticoagulation.
- •Direct Oral Anticoagulants (DOACs)
- Apixaban (10 mg BID × 7 days → 5 mg BID): $210–$270 (3-month course)
- •Parenteral + Vitamin K Antagonist (VKA)
- •Essential Diagnostic & Monitoring Fees
- CT Pulmonary Angiography (CTPA): $190–$230 - Lower-extremity Doppler ultrasound: $65–$85 - Serial ABG + troponin + BNP (per admission): $45–$60 - Inpatient monitoring (3–5 days, Grade 3A ward): $280–$420
Surgical / Interventional Procedures
*Eligibility Criteria:* High-risk PE (hemodynamic instability, shock, cardiac arrest), contraindication to thrombolysis, or failure of medical therapy.
- •Catheter-Directed Thrombolysis (CDT)
- •Surgical Pulmonary Embolectomy
- •Inferior Vena Cava (IVC) Filter Placement
- •Preoperative Workup (mandatory for all procedures)
- Transthoracic echocardiogram (TTE): $110–$140 - Pre-anesthesia evaluation + chest X-ray + ECG: $75
Special/Complex Condition Management
- •Massive PE with Cardiac Arrest (resuscitated): Urgent surgical embolectomy + VA-ECMO support: $12,500–$15,800 (includes 48-hr ECMO circuit, ICU monitoring)
- •Cancer-Associated PE: LMWH (dalteparin 200 IU/kg SC daily × 6 months): $1,350–$1,750 (total course)
- •Chronic Thromboembolic Pulmonary Hypertension (CTEPH) referral: Right heart catheterization + pulmonary angiography: $2,600–$3,100, followed by balloon pulmonary angioplasty (per session): $3,400–$4,200
Quick Selection Guide
- •<65 years, low-risk, no comorbidities, budget-conscious: DOAC monotherapy + outpatient follow-up ($180–$270)
- •≥65 years, renal impairment (CrCl 30–50 mL/min), high bleeding risk: LMWH bridging + VKA with close INR monitoring ($220–$310)
- •Hemodynamically unstable, no bleeding contraindications: IV unfractionated heparin + systemic thrombolysis ($140–$190, excludes ICU cost)
- •Contraindicated to all anticoagulants (e.g., active GI bleed): IVC filter + delayed anticoagulation ($1,400–$1,900 + $120–$160)
- •Recurrent PE on therapeutic anticoagulation: IVC filter + escalation to LMWH or DOAC dose adjustment ($1,520–$2,060)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended DVT-induced Pulmonary Embolism Medical Vacation Packages
Curated transparent all-inclusive packages combining DVT-induced Pulmonary Embolism treatment with China top medical destinations:
